-
Advances in testing for human papillomavirus-mediated head and neck cancer. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2024-03-20 Hisham Mehanna, Laia Alemany, Christian von Buchwald
New evidence has recently emerged regarding the utility and benefits of dual p16INKa (p16) and Human papillomavirus (HPV) status testing when determining the diagnosis and prognosis of patients with oropharyngeal cancer.
-
Molecular and nutritional markers in head and neck cancer. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2024-03-01 Gerard Milano, Jocelyn Gal, René-Jean Bensadoun
There is still a need of biomarkers in the induction and neoadjuvant settings for squamous cell carcinoma of the head and neck (SCCHN). The objective of this concise review article is to give an overview on both predictive and prognostic biomarkers potentially useful for the management of SCCHN.
-
Stereotactic ablative radiation therapy in metastatic prostate cancer. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2024-02-15 Soha Bazyar, Heather Mannuel, Phuoc T Tran
The evolving role of stereotactic ablative radiation therapy (SABR) as metastasis-directed therapy (MDT) for oligometastatic prostate cancer (omPCa) will be discussed.
-
Can we yet use tertiary lymphoid structures as predictive biomarkers for immunotherapy response in melanoma? Curr. Opin. Oncol. (IF 3.4) Pub Date : 2024-01-22 Francine Padonou, Thila Vanhulst, Mireille Langouo-Fontsa
In this review, we explore the potential of tertiary lymphoid structures (TLS) as predictive biomarkers in the response to immunotherapy for melanoma patients.
-
Explore & actuate: the future of personalized medicine in oncology through emerging technologies. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2024-01-22 Erald Babu, Subhojit Sen
The future of medicine is aimed to equip the physician with tools to assess the individual health of the patient for the uniqueness of the disease that separates it from the rest. The integration of omics technologies into clinical practice, reviewed here, would open new avenues for addressing the spatial and temporal heterogeneity of cancer. The rising cancer burden patiently awaits the advent of
-
Altered hormone expression induced genetic changes leads to breast cancer. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2024-01-19 Anchal Thakur, Navya Rana, Ranjit Kumar
Breast cancer ranks first among gynecological cancer in India. It is associated with urbanization, changes in lifestyle and obesity. Hormones also play a crucial role in the development of breast cancer. Steroid hormones play critical role in development of breast cancer.
-
Epigenetic dynamics of aging and cancer development: current concepts from studies mapping aging and cancer epigenomes. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2024-01-18 Shilpa Bisht, Yiqing Mao, Hariharan Easwaran
This review emphasizes the role of epigenetic processes as incidental changes occurring during aging, which, in turn, promote the development of cancer.
-
Tripartite motif family - its role in tumor progression and therapy resistance: a review. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2024-01-17 Yongqi Zhang, Ying Guan, Shuxiang Wang, Chunyan Guan, Xiaoli Liu
In this review, we summarized published articles on the role of tripartite motif (TRIM) family members in the initiation and development of human malignancies.
-
Pathology and new insights in thyroid neoplasms in the 2022 WHO classification. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-11-17 Laetitia Lebrun, Isabelle Salmon
The assessment of thyroid nodules is a common clinical problem, linked to the high incidence of thyroid nodules in the population and the low incidence of aggressive thyroid carcinoma. The screening is therefore one of the strengths of our patient care. Recently, the 2023 Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) and 2022 WHO classification of thyroid neoplasms have been released
-
Pathologic diagnosis of lung cancer - recent developments. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-11-09 Helmut Popper
Diagnosis of lung cancer has previously been based on the evaluation of resection specimen. However, approximately 80% of lung cancers are diagnosed in stage IV. Targeted therapy has changed the practice of pathology. Diagnosis is usually based on small biopsies or even needle aspirations. Subtyping is important, as a molecular classification has to be added.
-
Multiple endocrine neoplasia type 2: towards a risk-based approach integrating molecular and biomarker results. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-11-06 Andreas Machens, Henning Dralle
Significant advances have transformed our understanding of the molecular biology and natural history of multiple endocrine neoplasia type 2 (MEN2). This progress enacted a paradigm shift with regard to routine neck dissection for medullary thyroid cancer and total adrenalectomy for pheochromoytoma. The purpose of this review is to summarize key molecular and clinical data underpinning the current risk-based
-
Immune checkpoint inhibitors in elderly patients with lung cancer: evidence from phase 3 trials. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-11-02 Li Wang, Juan Zhou, Xin Yu, Chunxia Su
In this article, we aimed to summarize the results from recent phase III clinical trials that have evaluated the use of immune checkpoint inhibitors (ICIs) in elderly patients with lung cancer.
-
Immune checkpoint inhibitors as adjuvant therapy in patients with completely resected nonsmall cell lung cancer. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-10-23 Robert Pirker
The purpose of the review is to summarize the current status of immune checkpoint inhibitors as adjuvant therapy in patients with resected nonsmall cell lung cancer (NSCLC).
-
Is there role of adjuvant radiotherapy after complete resection of locally advanced nonsmall cell lung cancer? Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-10-23 Liyang Jiang, Xiangjiao Meng
This review aims to provide a timely and relevant overview of the role of postoperative radiotherapy (PORT) in completely resected stage IIIA-N2 nonsmall cell lung cancer (NSCLC). Given the controversy surrounding the use of PORT and the emergence of advanced radiation techniques and therapies, this review provides valuable insight into current and potential treatment strategies.
-
Neoadjuvant therapy with immune checkpoint inhibitors in operable nonsmall cell lung cancer. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-10-23 Rudolf M Huber
In localized nonsmall cell lung cancer (NSCLC) systemic recurrences after surgery are common. Therefore, adjuvant or neoadjuvant chemotherapy is used. With the advent of immune checkpoint inhibitors (ICIs) in metastatic disease the question is whether ICIs can further improve the outcome.
-
Potential subtype-specific therapeutic approaches in small cell lung cancer. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-10-19 Lilla Horvath, Christian Lang, Kristiina Boettiger, Clemens Aigner, Balazs Dome, Zsolt Megyesfalvi
Small cell lung cancer (SCLC) remains one of the most aggressive thoracic malignancies with an especially dismal prognosis. While the detection of various targetable driver mutations and immune checkpoints have revolutionized the treatment of non-small cell lung cancer (NSCLC), there has been only modest therapeutic innovation over the past decades in SCLC. In this review, we aim to provide a brief
-
Management of neurofibromatosis type 1 associated tumors of central and peripheral nervous system. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-09-20 Marica Eoli
In recent years emerging evidence suggests that some tumor types, extremely rare in general population and understudied, can be observed in NF1 and neoplasms related with this condition harbor peculiar genetic and epigenetic features. The aim of this review is to summarize recent advances that, delving into the tumor complexity, have identified new diagnostic tools and potential tumor subtype that
-
Neurorehabilitation in brain tumours: evidences and suggestions for spreading of knowledge and research implementation. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-09-14 Michelangelo Bartolo, Domenico Intiso, Chiara Zucchella
The last few decades have seen an increase in life expectancy in brain tumour patients; however, many patients report sensory-motor and cognitive disabilities due to the tumour itself, but also to the effect of anticancer treatments (surgery, radiotherapy, chemotherapy), supportive treatments, as well as individual patient factors. This review outlines the principles on which to base neurorehabilitation
-
Unveiling the enigma of the blood-brain barrier in glioblastoma: current advances from preclinical and clinical studies. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-09-08 Mohammed H Ahmed, Michael Canney, Alexandre Carpentier, Maya Thanou, Ahmed Idbaih
Glioblastoma (GBM), the most prevalent primary brain malignancy in adults, poses significant challenges in terms of treatment. Current therapeutic strategies for GBM patients involve maximal safe resection, followed by radiotherapy with concurrent and adjuvant temozolomide. However, despite this multimodal approach for GBM, the prognosis of GBM patients remains dismal because of their inherent primary
-
Epidemiology trends and progress in breast cancer survival: earlier diagnosis, new therapeutics. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-09-08 Ottavia Amato, Valentina Guarneri, Fabio Girardi
In this review we will critically appraise the latest evidence on breast cancer (BC) survival trends and discuss how these may reflect breakthroughs in early diagnosis and treatment approaches. We will address the wide global inequalities in BC survival and review the ongoing initiatives aimed at improving cancer control worldwide.
-
Fms-like tyrosine kinase 3 positive acute myeloid leukemia. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-09-05 Alessandro Isidori, Giuseppe Visani, Felicetto Ferrara
Fms-like tyrosine kinase 3 (FLT3) mutations are common in newly diagnosed patients with acute myeloid leukemia (AML). They are associated with a high risk of relapse. The identification of FLT3 mutations has important implications for the management of AML. FLT3 inhibitors have shown improved outcomes in FLT3-positive AML when used as a single agent in the salvage setting. However, the combination
-
Preclinical glioma models in neuro-oncology: enhancing translational research. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-09-01 Serena Barachini, Mariangela Morelli, Orazio Santo Santonocito, Chiara Maria Mazzanti
Gliomas represent approximately 25% of all primary brain and other central nervous system (CNS) tumors and 81% of malignant tumors. Unfortunately, standard treatment approaches for most CNS cancers have shown limited improvement in patient survival rates.
-
Schwannomatosis: a Realm Reborn: year one. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-09-01 Martin Planet, Michel Kalamarides, Matthieu Peyre
In 2022, an international consensus recommendation revised the nomenclature for neurofibromatosis type 2 (NF2) and Schwannomatosis (SWN), now grouped under the umbrella term Schwannomatosis, and defined new diagnostic criteria.
-
Machine learning applications and challenges in graft-versus-host disease: a scoping review. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-09-01 Ali Hassan Mushtaq, Areez Shafqat, Haneen T Salah, Shahrukh K Hashmi, Ibrahim N Muhsen
This review delves into the potential of artificial intelligence (AI), particularly machine learning (ML), in enhancing graft-versus-host disease (GVHD) risk assessment, diagnosis, and personalized treatment.
-
Recent advances in allogeneic transplantation for acute myeloid leukemia. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-08-30 Juan Montoro, Aitana Balaguer-Roselló, Jaime Sanz
This review highlights recent advancements in allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with acute myeloid leukemia (AML).
-
New strategies for the treatment of breast cancer with leptomeningeal metastasis. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-08-29 Sonya M Chew, Andrew D Seidman
Leptomeningeal metastasis is a complication of metastatic breast cancer that has a rising incidence likely due to the increased availability of novel systemic therapies, which have improved survival with better extracranial disease control but with limited intracranial efficacy. A poor prognosis of less than 6 months has historically been associated with leptomeningeal metastasis and it is often an
-
Promises of oncolytic viral therapy for adult and children with brain glioma. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-08-29 Ana Patiño-García, Marta M Alonso, Jaime Gállego Pérez-Larraya
The purpose of this review is to give an overview of early clinical studies addressing the safety and efficacy of oncolytic immunovirotherapy in adults and children with brain gliomas, and to highlight the extensive potential for the development of this therapeutic alternative.
-
Clinical utility of genomic signatures for the management of early and metastatic triple-negative breast cancer. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-08-22 Grazia Castellano, Federica Giugliano, Giuseppe Curigliano, Antonio Marra
This comprehensive review aims to provide timely and relevant insights into the current therapeutic landscape for triple-negative breast cancer (TNBC) and the molecular features underlying this subtype. It emphasizes the need for more reliable biomarkers to refine prognostication and optimize therapy, considering the aggressive nature of TNBC and its limited targeted treatment options.
-
Measurable residual disease in peripheral blood in myeloma: dream or reality. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-08-15 Tadeusz Kubicki, Benjamin A Derman, Dominik Dytfeld, Andrzej J Jakubowiak
Therapeutic advancements in multiple myeloma have led to increasingly deeper and more durable responses, creating a need for highly sensitive and applicable techniques for measurable residual disease (MRD) assessment. Bone marrow assays can deeply assess for MRD, but it is not conducive to performing frequent and dynamic evaluations, which may be needed for MRD-adapted treatment approaches. Recently
-
Fasting-mimicking diet: a metabolic approach for the treatment of breast cancer. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-07-31 Francesca Ligorio, Leonardo Provenzano, Claudio Vernieri
Metabolic reprogramming is a new and potentially targetable hallmark of cancer. In recent years, fasting and fasting-mimicking diets (FMDs) have been tested as anticancer strategies both in preclinical experiments and in clinical trials. In this review, we aim at summarizing the available evidence about the antitumour activity of these approaches in preclinical breast cancer models, as well as results
-
Surrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-07-25 Kristin Wright, Abhenil Mittal, Bishal Gyawali
Health technology assessment (HTA) of cancer drugs is important to identify whether drugs should be publicly funded. With increasing use of surrogate end points in clinical trials including breast cancer, a review of literature was done to synthesize evidence for validation of these surrogate end points and their potential role in HTA decisions pertaining to breast cancer.
-
T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-07-25 Niels W C J van de Donk, Chloe O'Neill, Maaike E M de Ruijter, Christie P M Verkleij, Sonja Zweegman
B-cell maturation antigen (BCMA)-directed T-cell immunotherapies, such as chimeric antigen receptor T-cells (CAR T-cells) and bispecific antibodies (BsAbs) have markedly improved the survival of triple-class refractory multiple myeloma (MM). However, the majority of patients still develops disease progression, underlining the need for new agents for these patients.
-
Precision medicine in extended adjuvant endocrine therapy for breast cancer. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-07-20 Megan E Tesch
In this review, the evolving role of currently available genomic assays for hormone receptor-positive, early-stage breast cancer in the selection of patients for extended adjuvant endocrine therapy will be discussed.
-
First line treatments in primary central nervous system lymphomas in young patients. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-07-19 Laurence Schenone, Marion Alcantara, Caroline Houillier, Carole Soussain
The aim of this review is to provide an update on current first-line treatments as well as on-going studies in immunocompetent patients with primary central nervous system lymphomas.
-
New hopes in relapsed refractory primary central nervous system lymphoma. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-07-18 Teresa Calimeri, Carolina Steidl, Paolo Fiore, Andrés J M Ferreri
Patients with relapsed/refractory primary central nervous system lymphoma (rrPCNSL) have poor prognosis, with a median survival after relapse of 6.8 months. In this review, we discuss the evolving landscape and the possible future directions related to this important unmet clinical need.
-
Primary central nervous system lymphoma (PCNSL) in older patients. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-07-18 Alexandre Bertucci, Vincent Harlay, Olivier Chinot, Emeline Tabouret
Primary central nervous system lymphoma (PCNSL) is a rare, chemo and radio-sensitive tumor limited to the central nervous system. The incidence of PCSNL increases notably in the elderly population which represented approximately half of the patients. The limit of 'elderly' population remained debated and nonuniform, including 60 years as a cutoff for brain radiotherapy, 65 years for autologous stem-cell
-
New boundaries for fertility sparing management in endometrial cancer. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-07-18 Alexandros Rodolakis, Vasilis Pergialiotis, Nikolaos Thomakos
The increasing rates of endometrial cancer in premenopausal women that accompanies modern lifestyle options that enhance the prevalence of obesity as well as the trend of delayed childbearing are expected to increase the need for fertility sparing techniques. Currently, the cornerstone of fertility sparing treatment is hormonal handling with progestin treatment and is reserved for women with well differentiated
-
Controversies in central nervous system prophylaxis of high-risk diffuse large B-cell lymphoma. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-07-14 Sabela Bobillo, Matthew R Wilson, Kate Cwynarski
Central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) is an uncommon but devastating complication with an overall survival of less than 6 months. This article will review the recent updates on CNS prophylaxis including new potential advances in the identification of high-risk patients.
-
Ovarian stimulation and oocyte cryopreservation in females with cancer. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-07-14 Kutluk H Oktay, Volkan Turan
We reviewed the most recent developments including the safety and effectiveness data and success rates in individualized ovarian stimulation protocols for adult and postpubertal females with cancer.
-
Ovarian preservation in gynecologic oncology: current indications and techniques. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-07-14 Nicolò Bizzarri, Matteo Pavone, Matteo Loverro, Denis Querleu, Anna Fagotti, Giovanni Scambia
Early menopause represents a relevant clinical issue for women. Nevertheless, this issue should be balanced with the risks of ovarian metastasis, ovarian recurrence, and the risk of recurrence in hormone-sensitive gynecological cancers. The purpose of this review was to provide an overview on current indications and techniques of ovarian preservation in patients with gynecological cancers.
-
Pathology and new insights in central nervous system lymphomas. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-07-12 Laetitia Lebrun, Sacha Allard-Demoustiez, Isabelle Salmon
Primary central nervous system lymphoma (PCNSL) is a rare central nervous system (CNS) malignancy, which represents a heterogenous group of tumors. Among PCNSL, diffuse large B-cell lymphoma of the CNS (CNS-DLBCL) represents the most common tumor type. Multiomics studies have recently revealed the complex genomic landscape of these rare diseases. These findings lead to a potential new molecular and
-
Application of natural killer immunotherapy in blood cancers and solid tumors. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-07-10 Mark Sayegh, Shoubao Ma, Jianhua Yu
Natural killer (NK) cells are innate lymphoid cells characterized by their ability to attack aberrant and cancerous cells. In contrast to the activation of T-cells, NK cell activation is controlled by the interaction of NK cell receptors and their target cells in a manner independent of antigen organization. Due to NK cells' broad array of activation cues, they have gained great attention as a potential
-
Clinician's guide to targeted estrogen receptor degradation using PROTAC in patients with estrogen receptor-positive metastatic breast cancer. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-07-10 Albert Grinshpun
PURPOSE OF REVIEW Metastatic breast cancer (MBC) remains a major clinical challenge, necessitating the development of innovative therapeutic strategies. Estrogen receptor (ER) degradation using proteolysis-targeting chimeras (PROTAC) has emerged as a promising approach for overcoming acquired resistance to endocrine therapy. This review will summarize recent findings, highlighting the role of ER degradation
-
HER2-positive breast cancer: cotargeting to overcome treatment resistance. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-07-07 Paola Zagami, Luca Boscolo Bielo, Eleonora Nicolò, Giuseppe Curigliano
The introduction in clinical practice of anti-HER2 agents changed the prognosis of patients with HER2-positive (HER2+) breast cancer in both metastatic and early setting. Although the incomparable results obtained in the last years with the approval of new drugs targeting HER2, not all patients derive benefit from these treatments, experiencing primary or secondary resistance. The aim of this article
-
Safety of assisted reproductive techniques in gynecological cancer patients. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-07-07 Sergio Caballero, Javier Domingo, Juan Antonio Garcia-Velasco
Gynecological cancer is a very important cause of comorbidity and mortality in women. The current delay in motherhood is increasing the incidence of women under 40 years of age that have not yet achieved their maternity goals when they are diagnosed and standard treatment negatively impacts the reproductive potential of cancer survivors. In this review, we update the information available about the
-
Current limits of conservative treatment in ovarian cancer. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-07-07 Myriam Gracia, María Alonso-Espías, Ignacio Zapardiel
Fertility-sparing surgery in ovarian cancer is an increasing need in gynecology-oncology clinical practice because of the frequent childbearing delay in developed countries. As the evidence in literature is based on observational studies, this review focuses on summarizing the most recent and relevant evidence for the conservative management of young patients with ovarian cancer.
-
Update on bi-specific monoclonal antibodies for blood cancers. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-07-05 Geoffrey Shouse
The purpose of this review is to present updates in the field of bispecific antibodies focusing on those agents that have been recently approved for multiple myeloma, follicular lymphoma and diffuse large B cell lymphoma.
-
Preclinical models to understand the biology and to discover new targets in brain metastases. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-06-30 Nadège Kindt, Nuria Kotecki, Ahmad Awada
Incidence of brain metastases increases overtime therefore it is important to rapidly progress in the discovery of new strategies of treatment for these patients. In consequence, more and more preclinical models of brain metastases (BM) are established to study new treatments for melanoma, lung, and breast cancer BM. Here, we reviewed the most recent findings of new drugs assessed in BM mouse preclinical
-
Recent advances in precision medicine for acute myeloid leukemia. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-06-29 Alberto Hernández-Sánchez, Lars Bullinger
Acute myeloid leukemia (AML) is a heterogeneous disease, in which treatment response and patient survival are highly conditioned by the leukemia biology. The aim of this review is to summarize recent advances in AML classification, risk stratification models, measurable residual disease (MRD) and the increasing number of treatment options that are paving the way towards precision medicine in AML.
-
Immunotherapy for inflammatory breast cancer: current evidences and future perspectives. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-06-27 Carmine Valenza, Dario Trapani, Giuseppe Curigliano
Inflammatory breast cancer (IBC) is the most fatal type presentation of clinical breast cancer. The immune tumor microenvironment (TME) of IBC is characterized by signals of immune evasion but suggests actionable vulnerability to immune-checkpoint inhibitors (ICIs). In this review, we aimed to summarize the most important preclinical evidences of IBC immune-vulnerability and the first data from clinical
-
Circulating tumor DNA in breast cancer: a biomarker for patient selection. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-06-27 Elisa Agostinetto, Guilherme Nader-Marta, Michail Ignatiadis
This review aims to explore the role of circulating tumor DNA (ctDNA) as a biomarker for patient selection in breast cancer. We describe the current evidence and the main ongoing trials both in the early and metastatic setting.
-
Neoadjuvant chemotherapy for resectable colon cancer in the era of precision oncology: a step forward or a step back? Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-07-01 Alessandro Audisio,Roberta Fazio,Alain Hendlisz,Francesco Sclafani
-
Two is company, is three a crowd? Triplet therapy, novel molecular targets, and updates on the management of advanced renal cell carcinoma. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-5-25 Taylor Goodstein, Yuanquan Yang, Karie Runcie, Ramaprasad Srinivasan, Eric A Singer
The purpose of this review is to highlight the most recent changes in the management of advanced renal cell carcinoma, a complicated and ever-changing field of research.
-
Doxorubicin combined with Trabectedin in systemic first-line M+/recurrent leiomyosarcoma patients. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-05-19 Margherita Turinetto, Pierre Meeus, Isabelle Ray-Coquard
Currently, the only systemic therapy approved for advanced leiomyosarcoma is Doxorubicin-based monotherapy. Despite disappointing progression-free survival (PFS) and overall survival (OS), no combination therapy has formally ever proven to be more effective. In this clinical setting, selecting the most efficient therapy is key, as most patients become quickly symptomatic with poor performance status
-
Advance care planning in oncology: a scoping review and some recommendations. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-05-16 Yves Libert, Lisa Choucroun, Darius Razavi, Isabelle Merckaert
Cancer patients' communication with their relatives and healthcare professionals (HCPs) is essential for advance care planning (ACP). The purpose of this scoping review was to synthesize recent research findings about factors enabling cancer patients', their relatives', and physicians' communication about ACP, and to propose recommendations for future ACP implementation in cancer care.
-
Adjuvant and neoadjuvant approaches in pancreatic cancer. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-05-15 Thierry Conroy, Aurélien Lambert, Michel Ducreux
Pancreatic cancer treatment remains a challenging problem for surgeons and oncologists. This review aims to summarize the current advances on adjuvant and neoadjuvant treatment approaches for resectable pancreatic cancer.
-
Treatment of radiation-associated angiosarcoma. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-05-15 Armelle Dufresne, Pierre Meeus, Marie-Pierre Sunyach
Radiation-associated angiosarcoma is a cutaneous aggressive tumor that is very rare and it represents a specific entity poorly studied in literature. It requires new therapeutic opportunity.
-
Following your gut: the emerging role of the gut microbiota in predicting and treating immune-related adverse events. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-05-12 Antoine Desilets, Arielle Elkrief
Although immune checkpoint inhibition has reshaped the therapeutic landscape leading to improved outcomes across an array of both solid and hematologic malignancies, a significant source of morbidity is caused by immune-related adverse events (irAEs) caused by these agents.
-
Next questions in the management of retroperitoneal sarcoma. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-05-10 Ashley Drohan, Alessandro Gronchi
Retroperitoneal soft-tissue sarcomas (RPS) are a group of rare, histologically distinct tumours with variable recurrence patterns depending on histological type. This review will discuss the growing body of evidence supporting histology-specific, multidisciplinary management and highlight areas of future research for patients with RPS.
-
Immunotherapies in non-metastatic gastrointestinal cancers. Curr. Opin. Oncol. (IF 3.4) Pub Date : 2023-05-10 Rita Saúde-Conde, Dan Nguyen, Alain Hendlisz
Over the last decade, immune checkpoint inhibitors have emerged as cornerstone in the treatment of many metastatic tumour types, including gastrointestinal cancers. In many solid tumours, the effective therapies in the metastatic field are progressively brought into the curative setting. Consequently, earlier tumoural settings have become a field of experiment for immunotherapies. In melanoma, lung